Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

Aclaris Therapeutics Inc. has gained IND clearance from the FDA for ATI-052, a bispecific anti-thymic stromal lymphopoietin (TSLP)/interleukin-4 receptor (IL-4R) monoclonal antibody being developed to ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has ...

About ATI-052 ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases. ATI-052 targets ...

Aclaris Therapeutics (NASDAQ:ACRS) said on Tuesday that the U.S. FDA has cleared its investigational new drug application to ...

The upcoming blinded, randomised trial will explore both single and multiple ascending doses of the bispecific monoclonal antibody, which is being developed for certain immuno-inflammatory conditions.

Context Therapeutics Inc.’s CNTX share price has dipped by 5.63%, which has investors questioning if this is right time to ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 6.65%, which has investors questioning if this is right time to ...